Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings is a leading biotech firm with a promising pipeline of T cell receptor-based bispecific immunotherapies for cancer, autoimmune diseases, and infectious illnesses. Immunocore's financial growth is driven by strong sales of its flagship product KIMMTRAK, and it has a substantial cash reserve to support its ambitious expansion plans and R&D investments. Immunocore's innovative immunotherapies offer unique advantages over competitors, such as CAR-T therapy, BiTE molecules, and checkpoint inhibitors, positioning the company for exceptional long-term growth.

Immunocore Holdings: Unlocking The Immune System's Hidden Potential

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

Immunocore Reports First Quarter 202 3 Financial Results and Provides Business Update

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Immunocore to present at the Bank of America Securities 2023 Health C are Conference

Immunocore to present at the Bank of America Securities 2023 Health Care Conference

Immunocore p resents new KIMMTRAK data confirm ing association between early ctDNA reduction and longer overall survival

Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

Immunocore to present at the 22 nd Annual Needham Virtual Healthcare Conference

Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference

Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It

Immunocore to present four posters at AACR Annual Meeting 2023

Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - Chief Executive Officer & Director Ralph Torbay - Head of Commercial Brian Di Donato - Chief Financial Officer & Head of Strategy David Berman - Head of Research & Development Conference Call Participants Michael Yee - Jefferies Patrick Trucchio - H.C. Wainwright Justin Kim - Oppenheimer Justin Zelin - BTIG Peter Lawson - Barclays Jeff Hung - Morgan Stanley Nick Gallo - Goldman Sachs Ahu Demir - Ladenburg Thalmann Operator Greetings.

Immunocore Holdings plc (IMCR) Q4 2022 Earnings Call Transcript

Immunocore Reports 2022 Financial Results and Provides Business Update

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?

Immunocore Holdings has strong, incremental sales and financials, a positive outlook. Total market dominance ensures demand for its products.

Immunocore Holdings: A Meteoric Rise Likely Here To Stay

Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?

Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March.

Biotech's Drug Pipeline Expands From Melanoma To Other Cancers

Amgen

Exact Sciences

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

Biotech leader Immunocore is just below its latest buy point ahead of quarterly earnings results. The post IPO Stock Of The Week: Biotech Leader Immunocore Approaches Latest Buy Point appeared first on Investor's Business Daily.

IPO Stock Of The Week: Biotech Leader Immunocore Approaches Latest Buy Point

Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock

Revance Therapeutics

Shockwave Medical

In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year.

3 Pharma Stocks That Will Mint Millionaires

Among the top IPO stocks to buy and watch, biotech leader Immunocore is approaching a new buy point in today's market action. The post IPO Stock Of The Week: Biotech Leader Immunocore Shows New Buy Point appeared first on Investor's Business Daily.

IPO Stock Of The Week: Biotech Leader Immunocore Shows New Buy Point

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Immunocore Holdings Stock (IMCR)